Author

Jos J. E. M. Kitzen

Observed names: J KITZEN, J Kitzen, J. J. E. M. Kitzen, J. J. Kitzen, J. Kitzen, J.J.E.M. Kitzen, Jos E.M.Kitzen, Jos J E M Kitzen, Jos J. Kitzen, Jos J.E.M Kitzen, Jos J.E.M. Kitzen, Jos JEM Kitzen, Jos Kitzen, Josef JEM Kitzen

Institution: Maasstad Ziekenhuis

Observed institutions: F. Hoffmann-La Roche AG, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Cancer Research UK, Erasmus MC, Albert Schweitzer Ziekenhuis, Maasstad Ziekenhuis, PharmaMar (Spain), Royal Marsden Hospital, Erasmus MC Cancer Institute, Daniel den Hoed Kliniek

ORCID: 0000-0003-0417-8052

Observed ORCID: 0000-0003-0417-8052

OpenAlex ID: A5109100395

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

2017 · Vivianne C G Tjan-Heijnen, Irene E G van Hellemond, et al. · The Lancet Oncology · 166

Aurora kinase inhibitors

2009 · J.J.E.M. Kitzen, M.J.A. de Jonge, et al. · Critical Reviews in Oncology/Hematology · 99

Effectiveness of a Hospital-Based Work Support Intervention for Female Cancer Patients – A Multi-Centre Randomised Controlled Trial

2013 · Sietske J. Tamminga, Jos H. A. M. Verbeek, et al. · PLoS ONE · 94

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

2009 · J.J.E.M. Kitzen, M.J.A. de Jonge, et al. · European Journal of Cancer · 89

Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel

2007 · Frederike K. Engels, Floris A. de Jong, et al. · The Oncologist · 80

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

2007 · G Attard, J Kitzen, et al. · British Journal of Cancer · 70

PDF

Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice

2020 · Nathalie I. Bouwer, Agnes Jager, et al. · The Breast · 61

PDF

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

2009 · Richard D. Baird, Jos Kitzen, et al. · Molecular Cancer Therapeutics · 48

PDF

A Hospital-Based Work Support Intervention to Enhance the Return to Work of Cancer Patients: A Process Evaluation

2012 · S. J. Tamminga, A. G. E. M. de Boer, et al. · Journal of Occupational Rehabilitation · 45

PDF

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

2021 · N. I. Bouwer, T. G. Steenbruggen, et al. · Breast Cancer Research and Treatment · 34

PDF

Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure

2017 · Irene E G van Hellemond, Ingeborg J H Vriens, et al. · JNCI Journal of the National Cancer Institute · 31

Irinotecan chemotherapy during valproic acid treatment: Pharmacokinetic interaction and hepatotoxicity

2007 · Floris A. de Jong, Jessica M. van der Bol, et al. · Cancer Biology & Therapy · 26

PDF

Two-Year Follow-Up of a Multi-centre Randomized Controlled Trial to Study Effectiveness of a Hospital-Based Work Support Intervention for Cancer Patients

2019 · S. J. Tamminga, J. H. A. M. Verbeek, et al. · Journal of Occupational Rehabilitation · 25

PDF

Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?

2019 · T. G. Steenbruggen, N. I. Bouwer, et al. · Breast Cancer Research and Treatment · 23

Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours

2011 · M.J.A. de Jonge, H. Dumez, et al. · European Journal of Cancer · 22

Association Between Geriatric Assessment and Post-Chemotherapy Functional Status in Older Patients with Cancer

2022 · Hánah N Rier, Marieke C Meinardi, et al. · The Oncologist · 20

PDF

Hepatic transport, Metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain

2006 · Floris A. de Jong, Jos J.E.M Kitzen, et al. · Cancer Biology & Therapy · 19

PDF

NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab

2019 · Nathalie I. Bouwer, Crista Liesting, et al. · Cardio-Oncology · 18

PDF

The Relevance of Microdialysis for Clinical Oncology

2006 · Jos E.M.Kitzen, Jaap Verweij, et al. · Current Clinical Pharmacology · 16

2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab

2021 · Nathalie I. Bouwer, Crista Liesting, et al. · Cardiovascular Ultrasound · 9

PDF

A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors

2005 · G. Attard, J. J. Kitzen, et al. · Journal of Clinical Oncology · 8

The effect of trastuzumab on cardiac function in patients with HER2 ‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction

2022 · Nathalie I. Bouwer, Tessa G. Steenbruggen, et al. · International Journal of Cancer · 7

Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: Results of a pharmacokinetic study

2009 · Jos J. Kitzen, Christian Puozzo, et al. · European Journal of Cancer · 7

The effect of (neo)adjuvant chemotherapy on long‐term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study

2023 · Selin Öztekin, Maartje J. Hooning, et al. · Cancer · 5

PDF

Surgeon reported treatment choices for AO type B and C thoracolumbar fractures without neurological deficits: An expert survey

2024 · J. Kitzen, W.M. Bakker, et al. · Injury · 4

Works count: 40

Citation count: 1,031

H-index: 18

I10-index: 19